The specificity of endothelial binding sites for heparin was investigated with heparin fractions and fragments differing in their Mr, charge density and affinity for antithrombin III, as well as with heparinoids and other anionic polyelectrolytes (polystyrene sulphonates). The affinity for endothelial cells was estimated by determining I50 values in competition experiments with 1251-heparin. We found that affinity for endothelial cells increases as a function of Mr and charge density (degree of sulphation). Binding sites are not specific receptors for heparin. Other anionic polyelectrolytes, such as pentosan polysulphates and polystyrene sulphonates, competed with heparin for binding to endothelial cells. Fractions of standard heparin with high affinity for antithrombin III also had greater affinity for endothelium. However, these two properties of heparin (affinity for antithrombin III and affinity for endothelial cells) could be dissociated. Oversulphated heparins and oversulphated low-Mr heparin fragments had lower anticoagulant activity and higher affinity for endothelial cells than did their parent compounds. Synthetic pentasaccharides, bearing the minimal sequence for binding to antithrombin III, did not bind to endothelial cells. Binding to endothelial cells involved partial neutralization of heparin. Bound heparin exhibited only 5 % and 7% of antifactor hIa and antifactor Xa specific activity, respectively. In the presence of 200 nM-antithrombin III, and in the absence of free heparin, a limited fraction (approx.
INTRODUCTION
Heparins are anticoagulant drugs which act by antithrombin III-mediated inhibition ofserine proteinases involved in blood coagulation. However, the antithrombotic properties of heparin fractions and fragments in vivo are not always quantitatively correlated with their anticoagulant potency in vitro (Jaques, 1980 (Jaques, , 1982 nor with their affinity for antithrombin III (AT III) (Barrowcliffe et al., 1984; Merton et al., 1984; Thomas, 1984) .
Binding of heparin to endothelial cells has been proven by experiments in vivo and in vitro (Hiebert & Jaques, 1976a,b; Mahadoo et al., 1978; Hiebert, 1981; Glimelius et al., 1978; Bauer et al., 1983; Barzu et al., 1984; Gajdusec, 1984) . Binding has been implicated as a possible indirect mechanism of antithrombotic action (Jaques, 1982; Vairel et al., 1983; Barrowcliffe et al., 1984; Fareed, 1985) despite a lack of data allowing a correlation of the antithrombotic effects of different heparins with their affinity for endothelial cells.
In a previous study we described the kinetics of binding of standard heparin and low-Mr heparin fragments to human endothelial cells in culture (Barzu et al., 1985) . Much lower affinity for endothelial cells was found with low-Mr fragments than with standard heparin. Our results also suggested that a fraction of standard heparin is internalized by endothelial cells, as was shown with other cell types (Bleiberg et al., 1983; Reyser et al., 1983; Castellot et al., 1985) . The aim of the present work was to elucidate whether endothelial binding sites for heparin are specific receptors, able to elicit a specific response, or are nonspecific binding sites, involved in heparin neutralization and/or degradation. The specificity of binding sites was determined with various heparin fractions or fragments differing in their Mr, charge density, and AT III affinity, as well as with various analogues and polyanionic electrolytes. We also tried to determine whether binding and/or endocytosis contribute to the inactivation of heparin and to what extent these events might potentiate the antithrombogenic properties of the endothelial cells. We therefore examined the availability of endothelial bound heparin for interaction with AT III as well as the AT III-dependent antiproteinase activity ofendothelial bound heparin. Our results show that endothelial binding sites are not specific receptors for heparins. These binding sites are involved in partial neutralization of the anticoagulant activity of heparins.
binding proteins, vitamins, but a low concentration of total proteins) was a product ofIBF, France. Collagenase was obtained from Boehringer-Mannheim. Proteinase type XIV (Pronase), bovine serum albumin and Polybrene were products of Sigma. Chromogenic substrates (CBS 31.39 and 34.47 ) and purified human factor Xa was obtained from Diagnostica Stago, France. AT III purified from human plasma (Thaler & Schmer, 1975) and human thrombin generated from purified prothrombin by using the prothrombinase complex (Pletcher & Nelsestuen, 1982) were gifts from Dr. Lindhout (University of Limburg, the Netherlands). The concentration of AT III was calculated from AA1J cm = 5.7. The concentration of thrombin (specific activity 3000 NIH units/mg) was determined by active-site titration (Chase & Shaw, 1969 ) with p-nitrophenyl-p'-guanidinobenzoate hydrochloride.
The following heparins and low-Mr heparins were obtained from Institut Choay, Paris: porcine mucosal standard heparin (160 USP units/mg and 155 anti-Xa units/mg); partially desulphated and Bolton-Hunter derivatized heparin (8.9 nmol of aromatic residues/mg, 130 USP units/mg, 130 anti-Xa units/mg) as described by Dawes & Pepper (1979) ; CY 216 (2500-8000 Da) and CY 222 (1500-8000 Da) were obtained by chemical depolymerization with HNO2 and gel filtration (patent application in progress). Other heparin fractions (noted as A, B, C and D) were obtained by ion-exchange chromatography (Sache et al., 1982) and were kindly supplied by Dr Sache. High-affinity and low-affinity fractions were separated by chromatography on AT III-Sepharose (Hopwood et al., 1976) . Pentosan polysulphate (Hemoclar), its partially desulphated derivative (SR 24776) and nonsulphated pentosans were kindly supplied by Dr. Mafrand (Sanofi Recherche, Toulouse, France). Polystyrene sulphonates were purchased from Chrompack (Orsay-Les-Ulis, France).
Gel ifitration of hepain and heparin fractions
In order to compare the profiles of labelled and nonlabelled heparins, we used a column of Sephadex G-100 (fine grade) (145 cm x 2 cm) eluted with 0.2 M-NaCl. Homogeneous oligosaccharides (hexa-, octa-and dodeca-saccharides) as well as the 8000-Mr fraction were obtained from CY 222 by gel filtration on Sephadex G-50 (superfine grade) (300 cm x 2.5 cm) eluted with 0.2 M-NaCl. The degree of polymerization of the compound was deduced from analysis of the chromatogram and confirmed by 13C-n.m.r. analysis for hexa-and octa-saccharide. The compounds were desalted by gel filtration on Sephadex G-25 with water as eluent.
M, determination
The Mr of heparin preparations was obtained by h.p.l.c. with TSK SW 2000 (Toyo Soda, Japan) or Lichrospher Si 100 (Merck, Germany) columns. The columns were calibrated using standards of known Mr previously determined by ultracentrifugation (Barlow, 1983) . Mr values for oligosaccharides (hexa-, octa-and dodeca-saccharides) were deduced from their degree of polymerization assuming an Mr of 316 for the average monosaccharide. Mr values of polystyrene sulphonates, pentosan polysulphate and related compounds were provided by the manufacturers.
Degree of sulphation
Degree ofsulphation was determined by conductometry according to Casu & Gennaro (1975) . The degree of sulphation of pentosan polysulphonates was provided by the manufacturer.
Labelling procedure
Standard, derivatized heparin (see under 'Chemicals'), was labelled with stoichiometric amounts of Na1251 according to Greenwood et al. (1963) by the chloramine T method, as described previously (Barzu et al., 1984) . Antithrombin activity and the gel filtration pattern on Sephadex G-100 of labelled heparin were compared with the same parameters of derivatized standard heparin and found to be practically identical. The specific radioactivity of labelled heparin was 15-17 mCi/mg. At 1 week after labelling, the radioactive ligand was dialysed for 24 h against phosphate-buffered saline at 4°C, using a membrane with a cut-off of 3500 Da, to avoid any trace of free 125I resulting from radiolysis.
Cell culture
Primary cultures of human umbilical vein endothelial cells were prepared according to Jaffe et al. (1973) and were allowed to grow in 35 mm Petri dishes in medium M 199 supplemented with 20% (v/v) fetal calf serum, 20,mol of glutamine/ml, 50 units of penicillin/ml and 50 units of streptomycin/ml at 37°C in a humid atmosphere containing 5% CO2. Monolayers were confluent by days 5-6 [(6-8) x 105 cells/dish]. The identity of endothelial cells was confirmed by immunofluorescent demonstration of the presence of factor VIII-related antigen as described by Booyse et al. (1981) .
Binding experments
At 24 h before each experiment the medium containing fetal calf serum was removed and cultures were washed and changed to medium containing 2% Ultroser G. This medium was again changed just before the experiment. As previously shown (Barzu et al., 1985) medium containing Ultroser G did not interfere with the binding of heparin to endothelial cells, but prevented cell detachment during repetitive manipulation. Binding was performed during a 5 h incubation with 10 pmol of 125I-heparin/dish in the presence of different unlabelled compounds. After incubation, cells were gently washed three times with 1.5 ml of phosphate-buffered saline, then detached and solubilized by incubation for 30 min at 37°C with 0.5 ml of phosphate-buffered saline containing 1 mg of Pronase/ml and 0.1% Triton X-100. The radioactivity of cell lysates and of the incubation medium was measured with a Beckman 7000 gamma counter. The affinity of the endothelium for different heparin fractions, fragments or analogues was indirectly determined from competition experiments, using a low concentration of labelled ligand (5 nm). Under these conditions the I50 value for unlabelled compounds could reflect the Kd (Hollenberger & Cuatrecasas, 1979; Naqui, 1983) and consequently the affinity of the compound for the endothelial cells. Each I50 value represents the mean of three or four experiments conducted in duplicate, with different batches of labelled heparins.
Determination of anti-I-a and anti-Xa activity of beparin bound to endothelial cells Confluent cells in 35 mm culture dishes were incubated for 5 h with medium M 199 and Ultroser G, in the absence or the presence of different concentrations of heparin, then washed five times with 1.5 ml of modified Hanks' balanced salt solution containing 1 mg of bovine serum albumin/ml and 15 mM-Hepes (pH 7.4). The reaction was carried out in 0.45 ml of washing buffer. AT III (25 1l of 0.5 isM) was added and preincubated for 5 min at 37 'C. The reaction was started by the addition of either 25 #1 of thrombin (0.1 sM) or 25 ul of factor Xa (0.1 #M). At different time intervals aliquots (40 1l) were taken to determine residual amidolytic activity. Aliquots were placed in spectrophotometric cuvettes containing 1 ml of 50 mM-Tris/HCl (pH 8), 175 mmNaCl, 0.5 mg of ovalbumin/ml and 0.4 mg ofPolybrene/ ml. Amidolytic activity was determined by following the absorption change at 405 nm after addition of either CBS 34.47 (94,UM), or CBS 31.39 (188/,M), which are specific chromogenic substrates for thrombin and factor Xa, respectively.
The pseudo-first order rate constant was estimated by plotting log(residual amidolytic activity) versus time. This rate constant was linearly related to the concentration of heparin in the measuring system, allowing the calculation of the anti-IIa and anti-Xa activities present in the cell culture dish or released in the medium. The anti-IIa and anti-Xa specific activities, k (min-' l,ug-1), were determined on the basis of the amount ofcell-bound or cell-released radioactivity, in experiments conducted with trace amounts of 1251-heparin, diluted in 0.2 /zM of unlabelled heparin.
RESULTS

Affinity for endothelium of the fractions of standard heparin separated by ion-exchange chromatography
Standard heparin is a heterogenous mixture of polysaccharide chains differing in Mr, degree of sulphation, and affinity for the specific receptor, AT III. In order to find out which of these components have a greater affinity for endothelium, four heparin fractions (A-D) separated by ion-exchange chromatography were tested for their ability to compete with 125I-heparin in binding to endothelial cells (Table 1) . These fractions were studied by Sache et al. (1982) for their anticoagulant activity in vitro and their affinity for AT III. It first appeared that their affinity for endothelial cells, as estimated by I50, increased as a function of charge density or degree of sulphation. However, it is important to point out that separation by ion-exchange chromatography, like other techniques of heparin fractionation, results in more than one structural variable at the same time (Hurst et al., 1983) . The fractions with higher charge density also had a higher Mr and greater proportion of chains with high affinity for AT III. Therefore we could not exclude the possibility that affinity for endothelium might also depend on Mr and/or affinity for AT III.
Affinity for endothelium as compared with affinity for AT m
To determine whether binding to endothelial cells requires the same structural factors as binding to AT III, we measured I,, values of high-and low-affinity fractions, separated by chromatography on AT IIISepharose (Table 2 ). High-affinity fractions exhibited approximately three times higher affinity for endothelial cells than did low-affinity fractions. To compare further the structural requirements, two synthetic oligosaccharides were also tested: a tetrasaccharide, which is completely devoid of affinity for AT III, and a pentasaccharide which contains the minimal sequence necessary for binding to AT III (Choay et al., 1983) . Neither the penta-nor the tetra-saccharide was able to compete with heparin binding to endothelial cells. Role of chain length and charge density in binding to endothelium
To establish the influence of the chain length on binding to endothelial cells, the affinity of different fractions or fragments of heparin was measured (Table  3) . Low-Mr heparin fractions, such as CY 216 or fraction A, have much lower affinity for endothelium than does standard heparin. Low-Mr heparin fragments such as CY 222 competed with no more than 30 % binding of standard heparin at 100 gSM (Barzu et al., 1985) . These results suggested that only the higher-Mr fragments from the mixture of CY 222 could bind to the endothelial cells. (Table 4) , despite its lower average Mr and its lower affinity for AT III (Fischer et al., 1982) . The affinity of pentosan polysulphate for endothelial cells was diminished by a partial desulphation (compound SR 24776). The nonsulphated parent pentosan was completely devoid of affinity for endothelium. Other sulphated polymers such as polystyrene sulphonates were also tested. As shown in Table 4 , they competed with heparin binding and their affinity was dependent on their Mr and their degree of sulphation.
Competition of 1251-heparin binding to endothelial cells by AT III
In our previous work (Barzu et al., 1985) , we showed that binding of radiolabelled heparin to endothelial cells in the presence of 20% fetal calf serum was five times lower than in the absence of serum. Many serum components might be responsible for this competition, including AT III, platelet factor 4, histidine-rich glycoproteins, and low density lipoproteins (Marciniak, 1974; Handin & Cohen, 1976; Lijnen et al., 1983;  Kecskes et al., 1983) . We studied the effect of purified human AT III on the binding of 1251-heparin, in the range ofconcentrations-forhigh affinitybinding. Concentrations of AT III higher than 10 nm inhibited binding, with an I50 value of 27 nm ( Fig. 1) . This result strengthened the data of Table 1 , which showed that the fractions of standard heparin having a high proportion ofhigh-affinity chains for AT III might be involved in binding to endothelium. Effect of AT m on the release of endothelial bound heparin Endothelial cells were prelabelled with 125I-heparin. The displacement ofthe bound fraction from endothelium by AT III was then investigated (Fig. 2) . Only high concentrations of AT III (approx. 100 times higher than bound heparin) were able to displace significantly more heparin than was spontaneously released (Fig. 2) . No displacement was found at the concentrations and at the short time of incubation (10 min) used in the kinetic study of anti-Ila or anti-Xa activities. Anti-Ha and anti-Xa activity of bound heparin
The AT HI-dependent antiproteinase activity of endothelium bound heparin as well as of the released fraction was measured. This was done in order to examine the role of binding in the neutralization of heparin and in the antithrombogenic properties of endothelium. Adequate conditions for pseudo-first-order kinetics of factor Ila and factor Xa inactivation reactions were selected. The rate of inactivation of the two proteinases was measured using albumin-coated dishes and dishes containing cell monolayer with or without previously bound heparin. No difference was ¶001 /so = 27 nM found in the kinetics of Iha or Xa inactivation between albumin-coated dishes and cell monolayers (Fig. 3 ). An anti-IIa and anti-Xa activity was found in dishes containing cells with previously bound heparin. These activities were dependent on the amount of heparin bound (results not shown). When cell supernatants were used for kinetic assays the activity was partially recovered, showing that the activity found in culture dishes is partially due to the release of a fraction of heparin from endothelial cells during incubation (Fig. 3) . Simultaneously, on the same primary cultures, we measured the amount of bound and released heparin, using '251-heparin as tracer. The total and specific antiproteinase activity of bound and released heparin was compared with the activity of heparin in solution (in the absence of cells). The activity of the bound fraction was very low: 5% and 7% for anti-Ila and anti-Xa activity respectively, as compared with standard heparin in solution (Table 5) . Moreover, the released heparin exhibited lower specific activity and a higher ratio of anti-Xa/anti-IIa activity as compared with applied material.
DISCUSSION
Binding of heparin to vascular endothelium has been described after intravenous injection into various animal species (Mahadoo et al., 1978; Hiebert, 1981) and was confirmed by incubating vessel segments (Hiebert & Jaques, 1976a,b) or cell cultures (Glimelius et al., 1978; Bauer et al., 1983; Barzu et al., 1984; Gajdusec, 1984) with heparin-containing medium. Binding was considered as evidence for an additional vascular mechanism of action of heparins (Jaques, 1982; Fareed, 1985; Barrowcliffe et al., 1984) . However, there is no experimental support to show that binding to endothelium has a significant effect on either the pharmacokinetics or action of heparin. In the present paper we studied the effect of binding of heparin to endothelial cells on its activity in the AT III-dependent inhibition of factors hIa and Xa. Since standard heparin is a heterogenous mixture of polysaccharide chains differing in Mr, charge density and affinity for AT III, it was necessary to establish the relative affinities of endothelial binding sites for the different components of the mixture. Our results show that higher-Mr fractions with high charge density bind more strongly to endothelial cells. The same fractions also contain a higher proportion of chains with high affinity for AT III (Table 1) , which is able to inhibit heparin binding to endothelium (Fig. 1) . It seems, however, that different structural factors are involved in binding to endothelial cells and in binding to AT III, since the synthetic pentasaccharide, bearing the minimal sequence involved in binding to AT III, did not compete with binding of heparin to endothelial cells. The correlation between binding to endothelial cells and affinity for AT III (Table 2 , lines 2 and 3) could be secondary to a variation in chain length. As has been previously shown by Laurent et al. (1978) , affinity for AT III increases with Mr of the polysaccharide chains.
Binding to endothelial cells was strongly dependent on Mr. Low-Mr heparin fractions or fragments (generated by depolymerization) had very low affinity for endothelial cells. Therefore, there is no reason to consider that binding to endothelial cells is the basis for a vascular mechanism of action, especially as concerns low-Mr heparin.
Oversulphation of different heparin fractions or fragments induced a higher affinity for endothelial cells. Nonetheless, affinity continued to be dependent on Mr (Table 3 ). The anticoagulant activity in vitro of these randomly oversulphated compounds was significantly lower compared with the activity of parent compounds. Since oversulphation yields compounds with high affinity for endothelium and low AT III-dependent anticoagulant activity, these two properties of heparins can be dissociated. Oversulphation of heparin fractions emphasizes the importance of electrostatic interactions in binding to endothelial cells.
Other highly sulphated polysaccharides (pentosan polysulphate) having low affinity for AT III (Fischer et al., 1982) and sulphated organic polyanions (polystyrene sulphonates) also compete with heparin binding (Table 4 (Heuck et al., 1985) to platelet factor 4 (Lane et al., 1984) and to fibronectin (Ogamo et al., 1985) . It One of the natural mechanisms of the antithrombogenicity of endothelium should be the occurrence on the endothelial cells of 'heparin-like molecules' . The presence of such a heparin-like activity was demonstrated in organ perfusions , using bovine aorta segments (Stern et al., 1985) or by extraction from bovine or rat microvascular endothelial cells in culture ,1985 . In our experimental conditions (primary culture at confluence, chromogenic assay) the human umbilical vein endothelial cells did not exhibit a heparin-like activity. Our results are in agreement with data reported by Rodgers et al. (1983) working with bovine aorta endothelial cells in culture, in similar experimental conditions.
Here, the endothelial bound heparin slightly accelerated factor Ila and factor Xa inactivation by AT III. However, the bound fractions were less available to interaction with AT III (25 nM) and their activities represented respectively 5% and 7% of anti-Ila and anti-Xa activities of an equivalent amount of heparin in solution. These activities are partially provided by a release of a fraction of bound heparin into the incubation medium. It seems therefore unlikely that cell bound heparin could express full biological activity as an 'immobilized anticoagulant' (Larsson et al., 1980; Hatton et al., 1983) or mimic the action of the endogenous heparin-like compound reported by Marcum and coworkers , 1985 . Instead, binding to endothelial cells was accompanied by a neutralization of heparin. The fraction of heparin released into the medium exhibited lower specific activity and a higher ratio of anti-Xa/anti-IIa potency than the applied heparin. These results suggest that lower-Mr chains are released from the endothelial cells. Further investigations are necessary to verify the possibility that heparin is degraded following binding and endocytosis by the endothelial cells. In the presence of an excess of AT III in the medium and in the absence of free heparin, surface-bound heparin fraction is partially dissociated and therefore may represent a source of anticoagulant.
The question arises whether endothelial binding, neutralization and release of heparin occur in vivo, in the presence of physiological concentrations of AT III and other plasma proteins with high affinity for heparin. Several points must be emphasized when trying to extrapolate data obtained in vitro to conditions in vivo.
The inhibitory effect on heparin binding to endothelium was found with concentrations of AT III higher than 10 nM. But the ratio between the number of endothelial binding sites for heparin and the concentration of AT III in vivo is different from that in vitro. This difference is due to a much higher endothelial surface/blood volume ratio in vivo, especially in the capillary bed . It is therefore difficult to predict the relative distribution of heparin in vivo between AT III, other plasma proteins, and endothelial binding sites.
As mentioned above, uptake of heparin by endothelial cells has been found in vivo in animals after heparin administration (Mahadoo et al., 1978; Hiebert, 1981) . Moreover, the pharmacokinetics of standard heparin are consistent with the existence of a saturable (cellular) pool ofcompound (Caranobe et al., 1985) . This saturable pool was not found with low-Mr hleparin fragments (CY 222) which have much lower affinity for endothelium.
In conclusion, data obtained with human endothelial The authors are indebted to Dr. J. C. Lormeau for the determination of the anticoagulant activity in vitro of heparin fractions, to Dr. Susan Michelson for her comments during the preparation of the manuscript, to Dr. Claudine Soria for helpful discussions and to Catherine Philippe for secretarial assistance. The nursing services of St Antoine and Lariboisiere Hospitals are thanked for the supply of umbilical cords.
